Skip navigation

IMI Consortia Members


Follow this link for a listing of the Innovative Medicines Initiative (IMI) consortia members.



NOTE: All consortia members on this list have the benefits of the IMI Platinum Membership in CDISC and should receive the IMI login to the CDISC Members’ Area and a link to the electronic version of the Introduction to CDISC Standards book from IMI.


For further questions regarding CDISC membership or the CDISC eBook, please contact Sheila Leaman or Diana Harakeh.


CDISC IMI relationship:


The Innovative Medicines Initiative (IMI) is the world’s largest public-private partnership in drug research. By linking industry, academic teams, regulators and patients’ organisations in joint research and training projects, IMI is transforming the EU’s ecosystem for pharmaceutical R&D, making Europe a more attractive place for private investment in innovation. By sharing research results that have not been brought together previously, IMI project partners are building new methods, models and tools that will speed up the development of novel therapies. IMI is funded jointly by the European Union (€1 billion in cash) and EFPIA, the European Federation of Pharmaceutical Industries and Associations (€1 billion in in-kind contributions).


The Innovative Medicines Initiative Joint Undertaking (IMI) and the Clinical Data Interchange Standards Consortium (CDISC) are pleased to announce that they have signed an agreement and initiated activities to enhance the use of information gathered for the purpose of developing safer, more effective innovative medicines for patients. The agreement was spearheaded by Ann Martin, Principal Scientific Manager for Knowledge Management at IMI. “To effectively manage information across a variety of projects requires a common format at the elemental level,” stated Ms. Martin. “Our stakeholders felt strongly that it is good practice to adopt data standards. CDISC already provides such standards enjoying wide adoption in the pharmaceutical industry. The CDISC standards therefore could be considered as a default standard for research conducted through the IMI projects. Moreover, CDISC not only focuses on global clinical research, but also collaborates to harmonise with global healthcare standards bodies such as the International Organization for Standardization (ISO), Health Level Seven International (HL7) and the European Committee for Standardization (CEN) through a Joint Initiative Council (JIC).”


IMI, a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA), is the world’s largest public-private partnership initiative aiming to speed up the development of better and safer medicines. With its €2 billion research fund, IMI supports collaborative projects through consortia comprising academic experts, small and medium-sized enterprises, patients’ organisations, pharmaceutical companies, and regulators to support innovation in research and development in Europe. The IMI projects range from finding new biomarkers for the development of safer and more effective treatments for patients, to educating researchers and using electronic health records for various research purposes. Follow the link.